[PDF][PDF] Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors

T Muranen, F Meric-Bernstam, GB Mills - Cancer Cell, 2014 - cell.com
Cancer Cell, 2014cell.com
In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and
pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K)
inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational
combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K
inhibition is warranted.
In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.
cell.com